These findings indicate that the effects of gemigliptin on attenuation of liver inflammation and fibrosis in NASH models is ULK1-mediated autophagy pathway-dependent but is independent of AMPK (Figure 8D). Here, ULK1 is linked to metabolic dysfunction-associated steatohepatitis.